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Abstract 
Frailty, a condition involving increased risk of disability and mortality in older adults, has emerged as a reliable way 
to predict the effect of aging. Genomic instability may help to anticipate recognition of frail individuals and 
improving frailty outcomes. Our objective was to evaluate the potential of the micronucleus frequency, evaluated in 
lymphocytes and buccal cells, to anticipate frailty identification and improve diagnosis reliability. Our results, from a 
group of older adults over 65, showed that frail individuals had significantly higher frequencies of micronucleus in 
lymphocytes (19.16 ± 0.66 vs. 13.07 ± 0.78, p < .001) and of binucleated buccal cells (82.65 ± 3.42 vs. 37.16 ± 2.85, 
p < .001) and lower frequencies of pyknotic and condensed chromatin buccal cells, than nonfrail subjects. When 
cognitive status was considered, similar results were obtained. Moreover, the presence of frailty and cognitive 
impairment were independently related to increases in frequencies of lymphocyte micronucleus and binucleated 
buccal cells. Our results encourage the use of micronucleus frequency in lymphocytes as a complement to clinical 
parameters in frailty identification. However, these results have to be further evaluated in prefrail patients, to better 
understand the connection between genomic instability and frailty and to establish these parameters as actual 
biomarkers of frailty in clinical practice. 








Frailty in older adults is an important geriatric syndrome that represents a risk factor for poor health 
outcomes for those over 65 years old. Nowadays, there are several definitions of frailty; however, Morley 
and colleagues (1), in the Frailty Consensus Conference of 2012, reached the following consensus 
definition for physical frailty: “frailty is a medical syndrome with multiple causes and contributors that is 
characterized by diminished strength, endurance, and reduced physiological function that increases an 
individual’s vulnerability for developing increased dependency and/or death.” Those authors also agreed 
that frailty is potentially preventable and can be reversible in its early stages. This idea is also supported 
by several recent studies (2,3). 
 
Currently, several tools are employed to recognize frailty in older people. One of the most commonly 
used is the frailty phenotype criteria proposed by Fried and colleagues (4), which includes unintentional 
weight loss, exhaustion, low physical activity, slow walking time, and low grip strength. The major 
limitation of this assessment is the late identification of frailty, which is possible only after the onset of 
clinical manifestations. Therefore, to improve the clinical impact of frailty screening, it is necessary to 
develop new tools that allow a timely identification of those individuals more prone to develop this 
syndrome. The availability of these new tools would facilitate the implementation of personalized 
therapies and the improvement of health outcomes by means of prevention and intervention programs. 
Within this framework, cellular and molecular biomarkers have been proposed as a feasible end point to 
widen the definition of frailty (5) and to provide a more accurate identification of frail people in early and 
potentially reversible stages or prefrail status. 
 
Along an individual’s lifetime, DNA is exposed to exogenous stressors and endogenous agents that 
can damage it. Some of the lesions induced, for example, mutations and chromosomal rearrangements, 
lead to a gradual destabilization of the genome integrity called genomic instability, which is one of the 
main hallmarks of the aging process (6). The involvement of genomic instability in different age-related 
phenotypes has been previously reported as a consequence of the loss of balance between DNA damage 
and the correct function of cellular DNA repair mechanisms (6,7). However, recent studies reviewed by 
Gorbunova and Seluanov (8) suggest the possibility that this imbalance can be the cause of the aging 
process and age-related phenotypes, rather than its consequence. These authors suggested that not only 
mutations accumulate with age but also the rate of mutation accumulation increases with age, which 
could be due to the DNA repair pathways becoming less efficient (7). 
The evaluation of chromatin alterations could be important for a better understanding of mutations in 
age-related changes (8). The micronucleus (MN) test is one of the most commonly used methods for 
assessing chromosome damage. MN assay provides a reliable measure for both chromosome loss and 
chromosome breakage because MN is formed from chromosome fragments or whole chromosomes that 
lag behind during anaphase in cell division (9). MN frequency can be evaluated in different cells and 
surrogate tissues. For a number of reasons, including ease of sample collection and reproducibility, 
peripheral blood lymphocytes and exfoliated buccal cells are the most suitable, and consequently, the 
most frequently employed tissues for MN studies in human populations (10). 
 
The cytokinesis-block MN (CBMN) cytome assay performed in peripheral lymphocytes is a 
comprehensive system for measuring DNA damage (11); it has been regularly applied in human 
biomonitoring of genotoxic exposures and is increasingly used in preventive medicine and nutrition (12–
14). MN frequency is strongly associated with the aging process, and increases of this biomarker have 
been reported in several age-related diseases including cancer, diabetes, neurodegenerative diseases such 
as Alzheimer’s or Parkinson’s, and arthrosis (15,16). 
 
The buccal MN cytome (BMNCyt) assay is an attractive candidate for the study of human populations 
due to its noninvasive nature. This technique, firstly proposed by Stich and Rosin in 1983 (17), has been 
employed in multiple studies as a sensitive biomarker of genetic damage and cell death caused by 
lifestyle-related factors such as alcohol and tobacco consumption, or nutritional deficiencies, and 
environmental exposures to pollutants, medical procedures, as well as inherited genetic defects in DNA 
repair (11,18). Together with MN formation, this assay allows as well to identify other abnormalities 
indicative of different kinds of cellular alterations. These abnormalities are shown as alterations in the 
nuclear morphology, such as binucleated cells, nuclear buds, pyknosis, karyorrhexis, abnormally 
condensed chromatin, and karyolysis (19). 
 
The relationship between genome instability and frailty has not been established yet. It is not clear 
whether or in which way genome instability may influence the susceptibility to frailty, and even the few 
preliminary studies in this regard failed in finding any association (20). However, due to the well-founded 
belief that genome instability is involved in the frailty syndrome, given its strong association with aging 
and age-related diseases, further investigations should be carried out in this line. For this reason, the 
objective of the present study was to explore the possible relationship between genome instability and 
frailty status and to determine the suitability of MN assay as a potential biomarker to be employed for 
early identification of frailty. To this aim, MN frequency in both peripheral blood lymphocytes and 
exfoliated buccal cells, together with other cellular alterations in buccal mucosa, was evaluated in a 
population of Spanish older adults, classified as frail, prefrail, and nonfrail according to the Fried’s 
criteria (4). To provide a more comprehensive evaluation of clinical features associated with frailty, the 
possible association between nutritional status and cognitive impairment with the level of genomic 
instability was also evaluated. 
Materials and Methods 
Subjects and Sample Collection 
A total of 257 volunteer donors (84 males and 173 females), aged 65 years or more (79.4 ± 8.8, range 
65–102), were recruited from associations of retired older people and nursing homes located in Galicia 
(NW of Spain). A post hoc assessment of the statistical power of the study based on the MN frequency in 
lymphocytes, showed that—given the actual size of the three groups—the study had adequate statistical 
power (80%) to detect, with a type I error of 0.05, a minimum increase of 21.6% in frail versus nonfrail 
subjects and of 20.1% in prefrail versus nonfrail subjects (Post-hoc Power Calculator by 
www.ClinCalc.com). All donors, or their relatives in case of inability, signed an informed consent form 
and completed a questionnaire to collect demographic, lifestyle, and medical information. The study 
protocol followed the principles embodied in the Declaration of Helsinki and was approved by the 
University of A Coruña Ethics Committee (reference number CE 18/2014). Qualified staff with extensive 
experience in the gerontology field (i.e., psychologists, occupational therapists, nurses) was in charge of 
the clinical evaluation. To unify the criteria in completing the clinical evaluation, all staff members were 
equally trained prior to the start of the study. Participants were excluded if they were taking medications 
included in the Anatomical Therapeutic Chemical (ATC) category L (antineoplastic or 
immunomodulating agents) (21) or they had cancer or any chronic infection (e.g., HIV, HCV, HBV), or if 
they denied signing the informed consent. 
 
Table 1 shows the general characteristics of the study population. Due to the small number of current 
smokers and ex-smokers (n = 5 and n = 48, respectively) a new category, “ever smokers,” was created 
combining both conditions. Similarly, a single category was considered including together malnourished 
individuals (n = 14) and individuals at risk of malnutrition (n = 80). 
  
Table 1. Description of the Study Population 
 
Total Nonfrail Prefrail Frail p Value 
      
Total n (%)  257 (100) 39 (15.4) 131 (50.6) 87 (34.0) 
 
Gender n (%) 
 Males  84 (32.7) 26 (66.7) 36 (27.5) 22 (25.3) <.001b 
 Females  173 (67.3) 13 (33.3) 95 (72.5) 65 (74.7) 
 
Age (years old)a  79.4 ± 8.8 (65–102) 73.3 ± 5.6 (65–85) 77.1 ± 7.7 (65–100) 85.6 ± 7.8 (65–102) <.001c 
 65–69  43 (16.8) 12 (30.8) 29 (22.1) 2 (2.3) <.001b 
 70–74  41 (16.0) 11 (28.2) 26 (19.8) 4 (4.7) 
 
 75–79  47 (18.4) 10 (25.6) 24 (18.3) 13 (15.1) 
 
 80–84  46 (18.0) 5 (12.8) 27 (20.7) 14 (16.3) 
 
 ≥85  79 (30.9) 1 (2.6) 25 (19.1) 53 (61.6) 
 
Smoking habits, n (%) 
 Nonsmokers  199 (79.0) 22 (56.4) 102 (78.5) 75 (90.4) <.001b 
 Ever smokers  53 (21.0) 17 (43.6) 28 (21.5) 8 (9.6) 
 
 No. cigarettes/da  18.4 ± 13.8 (2–60) 16.1 ± 8.8 (3–40) 15.7 ± 13.9 (2–60) 31.4 ± 15.7 (20–60) .020c 
 Years smokinga  26.7 ± 16.6 (4–66) 19.4 ± 9.1 (10–34) 30.4 ± 18.7 (4–66) 29.3 ± 18.2 (6–52) .154c 
BMI (kg/m2)a  
28.5 ± 5.6 (16.5–
53.2) 
28.1 ± 3.2 (21.1–
35.1) 
29.1 ± 5.0 (18.9–
47.4) 
27.7 ± 7.0 (16.5–
53.2) 
.191c 
Nutritional status, n (%) 
 Normal nutrition status  158 (62.7) 35 (89.7) 106 (80.9) 17 (20.7) <.001b 
 At risk or malnourished  94 (36.3) 4 (10.3) 25 (19.1) 65 (79.3) 
 
 MNA-SF scorea  11.8 ± 2.5 (4–14) 13.3 ± 1.4 (8–14) 12.8 ± 1.7 (4–14) 9.7 ± 2.4 (4–14) <.001c 
Cognitive status, n (%) 
 No cognitive impairment  174 (69.6) 39 (100) 118 (90.1) 17 (21.2) <.001b 
 Cognitive impairment  76 (30.4) — 13 (9.9) 63 (78.8) 
 
Living conditions, n (%) 
 Family home  157 (61.1) 39 (100) 113 (86.3) 5 (5.7) <.001b 
 Family home + daycare 
center  
27 (10.5) — 4 (3.1) 23 (26.4) 
 
 Nursing home  73 (28.4) — 14 (10.6) 59 (67.9) 
 
Education years, n (%) 
 ≤8  115 (45.3) 19 (48.7) 73 (55.7) 23 (27.4) <.001b 
 9–17  96 (37.8) 12 (30.8) 32 (24.4) 52 (61.9) 
 
 >17  43 (16.9) 8 (20.5) 26 (19.9) 9 (10.7) 
 
      
 
Note: ANOVA = analysis of variance; BMI = body mass index. Boldfaced values mean statistical significance. 
aMean ± SD (range). bChi-square test (two tails). cANOVA test (two tails). 
Peripheral blood and buccal mucosa samples were collected by nurses and trained technicians. Whole 
blood was collected by venipuncture into Vacutainer tubes containing heparin as an anticoagulant for MN 
assay in peripheral blood lymphocytes. Exfoliated cells were obtained by gently swabbing oral mucosa on 
the inner side of both cheeks with a cytobrush and kept in a buffer solution (see below). Samples were 
transported to the laboratory immediately, where they were processed within 4 hours of collection. All 
samples were coded at the moment of collection and analyzed under blind conditions. 
  
Frailty Criteria 
All subjects included in the study were classified as frail (n = 87), prefrail (n = 131), or nonfrail (n = 
39) according to the five Fried’s criteria (4). Individuals positive for three or more criteria were classified 
as frail; those positive for one or two criteria were classified as prefrail, meanwhile those with no positive 
items were classified as nonfrail. 
Clinical Assessment 
The nutritional status of the participants in the study was screened using the Spanish version (22) of 
the Mini-Nutritional Assessment-Short Form (MNA-SF) (23). The sum of the MNA-SF score 
distinguishes between elderly patients with (i) normal nutritional status (MNA-SF between 12 and 14 
points); (ii) at risk of malnutrition (MNA-SF 8–11 points); and (iii) malnourished (MNA-SF 0–7 points). 
The Spanish version (24) of the Mini-Mental State Examination (MMSE) scale (25) was employed to 
evaluate the global cognitive status. MMSE scores, ranging from 0 to 30, were adjusted for age and level 
of education, and participants were considered as cognitively impaired if they scored ≤24. 
Lymphocyte Micronucleus Assay 
The CBMN assay was performed following the protocol described by Fenech (11). MN automated 
scoring was performed using a Metafer4 System fluorescence, connected to an Axio Imager Z2 
microscope (Carl Zeiss Microscopy GmbH, Jena, Germany), equipped with an Automated Slide Feeder 
x80, controlling the microscope components for automated focusing, light source adjustment (for bright 
field imaging), and fluorescence filter changes. A minimum of 2,000 binucleated (BN) cells per 
individual, 1,000 from each duplicate culture, were scored to determine the number of MN in 
lymphocytes (MN-L). After the automated scan, the image gallery was visually reviewed by an 
experienced scorer, following the criteria described by Fenech (11) for MN and BN cells, in order to 
reject unsuitable cells and to correct feature values if necessary. 
Buccal Micronucleus Assay 
The BMNCyt assay was performed as described by Thomas and colleagues (18). Slides were scored 
blindly by a single scorer in a Nikon E-800 fluorescence microscope with ethidium bromide filter. The 
scoring criteria for the distinct cell types and nuclear anomalies were based on those described by Tolbert 
and colleagues (26) and Thomas and colleagues (18). A minimum of 1,000 cells was scored to determine 
the frequency of each cell type in the sample, including basal and differentiated cells, binucleated cells 
(BN-B), condensed chromatin cells (Cond-chrom-B), karyorrhectic cells (Karyorrhectic-B), pyknotic 
cells (Pyknotic-B), and karyolytic cells (Karyolytic-B). A minimum of 2,000 differentiated cells was 
scored to analyze the number MN (MN-B) and the number of cells with nuclear buds (NBUD-B). 
Statistical Analysis 
Statistical analyses were carried out following the recommendations given by Thomas and colleagues 
(18) for the buccal MN cytome assay. The three groups of older adults (nonfrail, prefrail, and frail) were 
compared by sociodemographic factors (i.e., gender, age, living conditions, and years of education), 
lifestyle factors (i.e., smoking habit, alcohol consumption, and nutritional status), and clinical 
characteristics (i.e., body mass index [BMI] and cognitive status). The chi-square test was applied for 
categorical variables and the analysis of variance (ANOVA) for continuous variables. 
  
The effect of frailty status on MN tests parameters was preliminarily tested through ANOVA with the 
Tukey’s post hoc test. Kolmogorov–Smirnov goodness-of-fit test was applied to assess normal 
distribution of the data; only MN-L followed a normal distribution. A log-transformation of the data was 
applied to BN-B, and a square root transformation was applied to Karyorrhectic-B, to achieve a better 
approximation to the normal distribution. No improvement was achieved with transformation in all other 
parameters, so the Kruskal–Wallis test with Bonferroni’s correction was applied for univariate statistics. 
 
Best fitting multiple regression models were used to estimate the effect of frailty status, nutritional 
status, and cognitive status. All models included gender, age, BMI, and smoking habit (never/ever 
smokers). Poisson regression was carried out with NBUD-B, Cond-chrom-B, and Pyknotic-B, and 
negative binomial regression was fitted for MN-L, MN-B, BN-B, Karyorrhectic-B, and Karyolytic-B. 
Mean ratio (MR) was used as the point estimate of effect accompanied by its 95% confidence interval 
(95% CI). For those MN test parameters significantly influenced by frailty, cognitive status, and 
nutritional status new models were run including frailty and cognitive status or frailty and nutritional 
status mutually adjusted, and adjusting also by gender, age, BMI, and smoking habit. 
 
Partial correlation coefficients adjusted by gender, age, BMI, and smoking were used to estimate 
associations between MN tests parameters. The threshold of significance was established at 0.05. The 
statistical software used for the analyses were the IBM SPSS software package V. 20 (SPSS, Inc) and the 
STATA/SE software package V. 12.0 (StataCorp LP). 
Results 
A total of 257 older adults (age range 65–102, including 31% aged 85 and over) were included in this 
study. After clinical classification based on Fried’s criteria, 39 subjects (15.4%) were classified as 
nonfrail, 131 (50.6%) as prefrail, and 87 (34.0%) as frail (Table 1). Sixty-eight per cent (n = 89) of 
prefrail subjects showed only one frailty criterion, while 32% (n = 42) showed two frailty criteria. The 
most commonly reported positive item (96%, n = 126) was muscle weakness (low grip strength). 
Smoking was more frequent in the nonfrail group. Although the number of cigarettes smoked per day was 
higher in the frail smokers, no significant difference in the duration of smoking was observed among the 
three groups. The proportion of individuals malnourished or at risk for this condition was much higher 
among the group of frail (79.2%), than in prefrail (19.1%) or nonfrail (10.3%) and, accordingly, the 
MNA-SF score was significantly lower in the frail group. The presence of cognitive impairment was 
observed in 9.9% of prefrail subjects and in the 78.8% of frail subjects. No case of cognitive impairment 
was reported in the nonfrail individuals. All nonfrail subjects and the large majority of prefrails lived at 
family home. Most frail subjects lived in nursing homes, although a quarter of them lived at family home 
but attending daycare centers. The duration of education was similar in the nonfrail and prefrail groups, 
whereas frail subjects presented a significantly lower number of years of education. 
 
Table 2 shows the results of both MN assays in the nonfrail, prefrail, and frail groups. Buccal basal 
cells were not observed in any of the individuals analyzed, and all micronucleated buccal cells contained 
only one MN. Univariate analysis of data showed that the frequencies of MN-L and BN-B increased 
progressively with frailty status, showing significant differences when frail and nonfrail subjects are 
compared. On the contrary, decreases in the frail group were observed in the frequencies of Pyknotic-B, 
as compared with the other two groups, and Karyolytic-B, as compared to the group of nonfrail 
individuals. No differences were obtained for the frequencies of MN-B, NBUD-B, Cond-chrom-B, or 
Karyorrhectic-B. 
  
Table 2. Results of Micronuclei Evaluation in Lymphocytes and Buccal Cells in the Study Group, Classified According to Frailty 
Status (Univariate Analysis) 
  
Nonfrail  Prefrail  Frail  
p Valuea 
n Mean ± SE  n Mean ± SE  n Mean ± SE  
           
‰MN-L  37 13.07 ± 0.78  122 14.87 ± 0.45  83 19.16 ± 0.66b,c  <.001 
‰MN-B  30 0.70 ± 0.36  102 0.46 ± 0.10  81 0.75 ± 0.17  .582 
‰NBUD-B  30 0.10 ± 0.06  102 0.03 ± 0.02  81 0.02 ± 0.02  .151 
‰BN-B  30 36.17 ± 2.85  102 43.13 ± 2.18  81 82.65 ± 3.42b,c  <.001 
‰Cond-chrom-B  30 0.53 ± 0.40  102 0.04 ± 0.02  81 0.02 ± 0.02  .554 
‰Karyorrhectic-B  30 22.50 ± 3.12  102 18.96 ± 1.34  81 22.14 ± 2.06  .537 
‰Pyknotic-B  30 0.57 ± 0.14  102 0.33 ± 0.07  81 0.11 ± 0.04b,c  .001 
‰Karyolytic-B  30 3.37 ± 0.90  102 2.21 ± 0.26  81 2.63 ± 0.65b  .018 
           
 
Note: ANOVA = analysis of variance; MN-L = micronuclei in lymphocytes; MN-B = micronucleus in buccal cells; NBUD-B = 
nuclear buds in buccal cells; BN-B = binucleated buccal cells; Cond-chrom-B = buccal cells with condensed chromatin; 
Karyorrhectic-B = karyorrhectic buccal cells; Pyknotic-B = pyknotic buccal cells; Karyolytic-B = karyolitic buccal cells. Boldfaced 
values mean statistical significance. 
aMultiple group comparison (ANOVA or Kruskal–Wallis test). bStatistically different from nonfrail. cStatistically different from 
prefrail (Tukey’s test or Bonferroni’s correction). 
When correlations between MN-L and all parameters obtained in the BMNCyt assay were assessed, a 
significant association was only found for BN-B (r = .367, p < .001). In order to determine the single 
contribution of each frailty criterion to MN-L frequency, this parameter was compared in the groups of 
subjects negative and positive for each individual criterion (Figure 1). Highly significant increases in 
MN-L rate were observed in subjects positive for the criteria low physical activity, slow walking time and 
low grip strength when compared to those individuals negative for the corresponding criterion. No 





Micronuclei in lymphocytes (MN-L) frequency in the older adult population, according to each frailty criterion (4). The number of 
individuals included in each group is indicated inside each rod. *p < .05, **p < .001, significant difference with regard to negative 
(Student’s t test). Bars represent mean standard error. UWL = unintentional weight loss; E = exhaustion; LPA = low physical 
activity; SWT = slow walking time; LGS = low grip strength. 
  
Results obtained in the multivariate statistical analyses, adjusting for gender, age, BMI, and smoking 
habit, confirmed previous univariate analysis results (Table 3), that is, frail individuals showed a 44% 
significant increase in the frequency of MN in lymphocytes, a significant doubling of binucleated buccal 
cells, and significant decreases in the frequencies of pyknotic buccal cells, and of condensed chromatin 
buccal cells. Only in this last outcome, prefrail subjects presented a significant result, whereas all the 
other parameters did not significantly differ from nonfrail subjects. 
Table 3. Effect of Frailty Status on MN Tests Parameters in Lymphocytes and Buccal Cells 
 
‰MN-L   ‰MN-B   ‰NBUD-B   ‰BN-B  
  Mean Ratio 95% CI  Mean Ratio 95% CI  Mean Ratio 95% CI  Mean Ratio 95% CI 
Frailty status 








 Prefrail  1.07 (0.94–1.22)  0.77 (0.24–2.47)  0.39 (0.06–2.42)  1.14 (0.94–1.39) 
 Frail  1.44** (1.24–1.67)  1.23 (0.32–4.70)  0.41 (0.04–4.63)  2.06** (1.65–2.57) 
  ‰Cond-chrom-B  ‰Karyorrhectic-B  ‰Pyknotic-B  ‰Karyolytic-B 
Frailty status 








 Prefrail  0.15* (0.04–0.50)  0.84 (0.60–1.16)  0.72 (0.37–1.41)  0.68 (0.35–1.35) 
 Frail  0.13** (0.02–0.84)  1.02 (0.70–1.49)  0.29* (0.10–0.81)  0.85 (0.39–1.86) 
            
 
Note: CI = confidence interval; BMI = body mass index; BN-B = binucleated buccal cells; Cond-chrom-B = buccal cells with 
condensed chromatin; Karyolytic-B = karyolitic buccal cells; Karyorrhectic-B = karyorrhectic buccal cells; MN-B = micronucleus 
in buccal cells; MN-L = micronuclei in lymphocytes; NBUD-B = nuclear buds in buccal cells; Pyknotic-B = pyknotic buccal cells. 
Models are adjusted by age, sex, BMI, and smoking habit. Boldfaced values mean statistical significance. 
*p < .05; **p < .01. 
A borderline significant influence of age on the study outcomes was found for the frequency of MN-L 
and Pyknotic-B (MR = 0.99, 95% CI = 0.99–1.00, p = .022 and MR = 0.96, 95% CI = 0.92–1.00, p = 
.029, respectively). Females presented significantly higher rates of MN-L than males (MR = 1.18, 95% CI 
= 1.09–1.29, p < .001), but significantly lower values of Cond-chrom-B (MR = 0.16, 95% CI = 0.05–
0.55, p = .003). BMI influenced significantly and inversely the frequency of Karyolytic-B (MR = 0.96, 
95% CI = 0.92–0.99, p = .014). 
 
The possible influence of nutritional status and cognitive status on the various study parameters was 
assessed (Table 4). Individuals malnourished or at risk of malnutrition presented significantly higher 
values of MN-L and BN-B and significantly lower frequency of Pyknotic-B than individuals with normal 
nutrition. Equivalent results were observed for subjects with cognitive impairment, as compared to 
subjects with normal cognitive status. 
  
Table 4. Effect of Nutritional Status and Cognitive Status on MN Tests Parameters in Lymphocytes and Buccal Cells 
  
‰MN-L   ‰MN-B   ‰NBUD-B   ‰BN-B  
Mean 
Ratio  
95% CI   
Mean 
Ratio  
95% CI   
Mean 
Ratio  
95% CI   
Mean 
Ratio  
95% CI  
Nutritional status  
Normal nutrition  1.00     1.00     1.00     1.00    
At risk or malnourished  1.23**  (1.12–1.35)   1.38  
(0.55–
3.46)  
 0.73  
(0.11–
4.74)  
 1.50**  
(1.29–
1.75)  
Cognitive status  
No cognitive 
impairment  
1.00     1.00     1.00     1.00    
Cognitive impairment  1.40**  (1.27–1.55)   2.11  
(0.91–
4.88)  
 0.81  
(0.13–
5.18)  
 1.87**  
(1.61–
2.17)  
  ‰Cond-chrom-B   ‰Karyorrhectic-B   ‰Pyknotic-B   ‰Karyolytic-B  
Nutritional status  
Normal nutrition  1.00     1.00     1.00     1.00    
At risk or malnourished  1.57  
(0.17–
14.71)  
 1.27  
(1.01–
1.61)  
 0.39*  
(0.18–
0.88)  
 1.28  
(0.77–
2.11)  
Cognitive status  
No cognitive 
impairment  
1.00     1.00     1.00     1.00    
Cognitive impairment  0.35  (0.07–1.72)   1.08  
(0.84–
1.38)  
 0.28**  
(0.11–
0.73)  
 1.15  
(0.68–
1.94)  
            
 
Note: CI = confidence interval; BMI = body mass index; BN-B = binucleated buccal cells; Cond-chrom-B = buccal cells with 
condensed chromatin; MN-B = micronucleus in buccal cells; Karyolytic-B = karyolitic buccal cells; Karyorrhectic-B = 
karyorrhectic buccal cells; MN-L = micronuclei in lymphocytes; NBUD-B = nuclear buds in buccal cells; Pyknotic-B = pyknotic 
buccal cells. Models are adjusted by age, sex, BMI, and smoking habit. Boldfaced values mean statistical significance. 
*p < .05; **p < .01. 
When frailty status and cognitive status were mutually adjusted, the presence of frailty and cognitive 
impairment were independently related to an increase in the frequency of MN-L (MR = 1.22, 95% CI = 
1.02–1.46, p < .05 for frailty and MR = 1.25, 95% CI = 1.10–1.43, p < .01 for cognitive impairment) and 
BN-B (MR = 1.59, 95% CI = 1.23–2.05, p < .001 for frailty and MR = 1.45, 95% CI = 1.21–1.75, p < 
.001 for cognitive impairment), both of them remaining significant. A decrease of Pyknotic-B frequency 
remained, not any longer significant (MR = 0.54, 95% CI = 0.13–2.31, p = .404 for frailty and MR = 
0.38, 95% CI = 0.10–1.40, p = .146 for cognitive impairment). On the contrary, the inclusion of frailty in 
models fitting nutritional status reduced the strength of the association between this parameter and all end 
points of the cytome assay, which resulted not any longer significant. 
  
Discussion 
Frailty is a multidimensional geriatric syndrome characterized by increased vulnerability to stressors, 
resulting from a decline in reserve and function across multiple physiological systems. Hence, frailty is 
associated with an increased risk of adverse health outcomes including morbidity, disability, falls, 
hospitalization, institutionalization, and mortality (27). The association of genomic instability and the 
aging process has been widely described (7,8,28). Frailty is considered a consequence of the deregulation 
of several physiological systems (immune, endocrine, muscular) occurred during the aging process. For 
this reason, a direct association between frailty and genomic instability seems to be also plausible, and, 
accordingly, it has been previously assessed by evaluating different genomic biomarkers, including 
telomere length (29), DNA methylation (30), or DNA damage and repair impairment (31). Nevertheless, 
all these studies failed in finding a relationship between frailty and any of these genomic parameters. 
 
Since MN frequency is a well-established biomarker of genomic instability, and in order to address its 
suitability as a potential biomarker of frailty, in the present study MN formation in peripheral blood 
lymphocytes and exfoliated buccal cells was determined in a population of elder individuals classified as 
nonfrail, prefrail, or frail, according to the five phenotypic criteria proposed by Fried and colleagues (4). 
Results obtained showed a significant progressive increase in the frequency of MN-L with frailty severity, 
whereas no difference among groups was found in the frequency of MN-B. Although similar results 
would be initially expected from both approaches, this discrepancy between results obtained from 
lymphocytes and buccal cells was previously reported (e.g., in subjects with Down’s syndrome regarding 
healthy controls (32) and in Alzheimer’s disease patients and controls (16)). As suggested by Ferreira and 
colleagues (32), this may be due to differences in metabolism and/or apoptosis levels between exfoliated 
buccal cells and lymphocytes. In addition, buccal epithelial cells are considered short-lived cells due to 
their continuous renewal; therefore, the presence of MN in buccal mucosa has been mainly linked to 
recent exposure to genotoxic agents more than to fixed genetic damage (33), a condition that would 
contribute to explain the differences found in our study between the two tissues. 
 
As previously indicated, MN production was associated with aging and age-related diseases in both 
peripheral lymphocytes and buccal cells in a number of previous studies (10,15,28). Moreover, this 
biomarker has also been associated with features of the aging phenotype, including loss of function, 
mental retardation, disability, and death (34). However, to the best of our knowledge, this is the first study 
evaluating MN formation in buccal mucosa cells from frail older subjects and the second one in applying 
this approach to lymphocytes of older adults classified according to frailty status. Opposing to our results, 
this single previous study (35) failed in finding a relationship between frailty and MN-L frequency in an 
Italian elder population. However, in that work, no distinction was considered between prefrail and 
nonfrail groups, so they were analyzed together. This decision could have possibly masked the difference 
between frail subjects and nonfrail controls, due to the lower MN-L frequency in the prefrail group. 
Moreover, their sample population size was smaller (N = 180), and the regression models applied did not 
include BMI and smoking habit, which could have consistently contributed to explain the lack of 
association reported. 
 
Although in our study, the significant increase in MN-L frequency regarding the nonfrail subjects was 
only found in the frail group, prefrail individuals also showed a slight increase in this parameter, 
supporting a possible linear association between genomic instability and frailty. 
 
Another original result from this study refers to the different contributions of the five different frailty 
criteria (4) to the increase of the MN-L (Figure 1); low physical activity, slow walking time, and low grip 
strength contribute the most, whereas unintentional weight loss does not contribute at all. The lack of 
contribution of this last criterion was in some way unexpected, especially considering the observed effect 
of nutritional status on the final results (Table 4) and the previous studies linking diet deficiencies and 
chromosomal damage (36). However, it must be taken into account that unintentional weight loss in 
elderly, or aging-related sarcopenia, has multifactorial causes including disuse, changing endocrine 
function, chronic diseases, and so on, being nutritional deficiencies just one of them (37). 
  
Although less employed than the CBMN test, the BMNCyt assay in exfoliated cells is a useful and 
minimally invasive method for monitoring genetic damage in humans. It has been previously employed as 
a tool to evaluate age-associated genomic instability both in healthy individuals (25) and Down’s 
syndrome individuals, who experience premature aging (28,32). In these cases, a positive association 
between MN production and aging was found. Besides, an increase in MN-B frequency was previously 
reported in several age-related diseases such as diabetes (38), cancer (39), or rheumatoid arthritis (40). 
 
Tissue regenerative capacity depends on the number and division rate of the proliferating cells, along 
with genomic stability and propensity to cell death. This process is basic for healthy aging. Buccal 
mucosa offers the possibility to study the regenerative capacity of the epithelial tissue, in an easily 
accessible and noninvasive sampling procedure (18). Thus, together with MN evaluation, BMNCyt assay 
allows studying several endpoints for other nuclear abnormalities that occur during the normal cell 
division. These abnormalities have been previously employed as a biomarker of DNA damage (NBUD-
B), defects in cytokinesis (BN-B) and proliferative potential (basal cell frequency), and/or cell death 
(Cond-chrom-B, Karyorrhectic-B, Pyknotic-B, and Karyolytic-B) (19). 
 
Even though the rate of BN-B decreased significantly with age, it was found significantly higher in 
the frail group and showed a progressive increase with frailty severity. Thus, these results indicate 
alterations in the cytokinesis process, which could lead to alterations in cell proliferation, in frail subjects. 
Besides, decreases were obtained in buccal cell death parameters (Pyknotic-B, Karyolytic-B, and Cond-
chrom-B, the two former significant) in the frail group with regard to the other two. Since significant 
increases in apoptosis indicative parameters (Cond-chrom-B, Karyorrhectic-B) were previously observed 
in healthy older subjects (aged 65–70) as compared with younger individuals (aged 18–25) (41), our 
results may reflect important changes in the profile of the buccal mucosa related to frailty and not 
associated with age. 
 
The proportion of basal cells and cells undergoing cell death in buccal mucosa is an indication of the 
regenerative capacity of this tissue (18). In our study, no basal cells were found in the scored samples, 
possibly due to the subjects’ advanced age and the expected wear of their mucous tissue. Besides, the 
rates of cells undergoing cell death (Cond-chrom-B, Pyknotic-B, and Karyolytic-B) resulted significantly 
decreased in frail and prefrail groups, suggesting a minor regenerative capacity of the buccal mucosa in 
these individuals. 
 
Together with data on frailty, the possible influence of the nutritional status and the cognitive 
impairment of the study subjects on the obtained results were analyzed. Malnourishment is a common 
status in the elderly adults. In our study population, 14.6% frail individuals were malnourished, whereas 
79.2% frail and 19.1% prefrail individuals were at risk of being malnourished. When the influence of 
nutritional status on MN tests parameters was assessed, higher levels of MN-L and BN-B and lower 
levels of Pyknotic-B were observed in individuals malnourished or at risk of malnutrition regarding those 
with normal nutrition. These results coincide with those for frailty status, which is not unexpected 
because it has been previously described that those individuals with an impaired nutritional status are 
more likely to be frail (42). Furthermore, the frailty criterion unintentional weight loss is related to 
nutritional status, indeed “involuntary weight loss during the last three months” is one of the items 
included in the MNA-SF questionnaire. 
 
Micronutrient status plays an important role in the protection against genome damage by providing 
co-factors required for an efficient DNA repair, detoxification, or maintenance of genome methylation 
(43). Consequently, and in agreement with our results, vitamin and mineral deficiencies in diet could be 
associated with increased genomic damage and cancer risk (44). In this regard, Fenech and colleagues 
(45) also reported an increase in MN-L frequency in older men (aged 50–70) with nonoptimal values of 
serum folate and homocysteine regarding subjects with higher levels of these micronutrients. A complete 
review on the effects of dietary intervention on MN levels concluded that micronutrient supplementation 
(e.g., with vitamins, antioxidants, wine) could lead to a significant reduction of MN frequency, in both 
peripheral lymphocytes and buccal mucosa cells, in supplemented subjects (43). This observation, 
together with the influence of nutritional status found in the present study, would support the idea that 
MN-L frequency associated with frailty or prefrailty status could be reduced, at least in part, with a proper 
diet intervention in the elderly adults. 
 
A similar relationship was found when the influence of cognitive status was assessed. In particular, 
increases in MN-L and BN-B cells and a decrease in Pyknotic-B were observed in subjects with cognitive 
impairment. Supporting this last result, decreases in the buccal cell death parameters (Karyorrhectic-B, 
Cond-chrom-B) were previously observed in Alzheimer’s patients with regard to healthy controls (41). 
However, since the significant effect on MN-L and BN-B cells remained when both statuses were 
mutually adjusted, it seems that cognitive status has a strong influence on the obtained results. 
Accordingly, a relationship between frailty status and cognitive impairment has been previously described 
(46), as well as the association between MN frequency, as a biomarker of genomic instability, and 
cognitive impairment (41). This demonstrated association between both statuses, frailty and cognitive, 
strongly complicates the distinction between genomic or cellular alterations related to frailty condition 
and those due to cognitive impairment. The Fried’s criteria, frequently used in clinical settings and 
employed in the present study to identify frail people, do not consider cognitive features of the 
individuals, and consequently, the initial distinction between subjects with differential cognitive status 
cannot be conducted. However, more and more authors are increasingly claiming for differentiating 
physical frailty from cognitive frailty (47). Our results would support the need for this distinction in order 
to enhance reliability when testing the suitability of a potential biomarker for frailty identification. 
Conclusions 
Different studies support the reversibility of frailty status or its improvement by changes in diet, 
physical exercise, and medications (2,3). Identifying frail people as early as possible seems, therefore, 
crucial for geriatricians and health care professionals because it would allow to implement 
interdisciplinary and personalized cares and to improve outcomes by means of prevention and 
intervention programs. All this would lead to decrease the need for admission to nursing homes and 
hospitals, lowering the risk of dependence and death, and eventually improve the welfare and personal 
satisfaction, reducing the health, social, and economic costs associated with frailty. 
 
The use of biomarkers could result highly helpful in identifying frailty of prefrailty status. Given its 
sensitivity, specificity, objectivity, and predictive capacity, several authors have pointed out that cellular 
and molecular biomarkers may potentially be used for frailty identification (20). However, to date, no 
specific biological marker has been identified as a definitive marker for frailty. 
 
In order to deeply investigate this, the potential use of MN frequency, as an indicator of genomic 
instability, for frailty identification has been addressed in the present study. According to our findings, 
MN frequency evaluated in lymphocytes (as a marker of fixed or accumulated genetic damage), but not in 
buccal cells (reflection of recent damage) could be considered as a biomarker of frailty. Thus, these 
results demonstrate for the first time a direct relationship between frailty in older adults and genome 
instability. Even though this association resulted statistically significant only in the frail group, also 
individuals with a prefrail status showed an increase in the MN-L frequency, supporting this relationship 
and opening the door to further investigations in this line. Moreover, associations between frailty and cell 
death parameters were obtained from the BMNCyt assay, which supports the use of this minimally 
invasive method as a complement in frailty identification, at least in its advanced state, where these 
differences resulted statistically significant. 
 
In summary, our results support the use of MN frequency evaluated in lymphocytes for frailty 
identification. However, because this association was significant only when the frailty is phenotypically 
more evident and not in a prefrail status, which would be desirable from a clinical point of view, 
additional research is necessary to fully understand the connection between genomic instability and frailty 
syndrome in the elderly adults. Besides, given the influence of the individual cognitive impairment on the 
MN-L results, it is also necessary to determine the weight of cognitive impairment in this association 
prior to establishing this parameter as an actual biomarker of frailty in clinical practice.  
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